Historical Archive

Teva: disappointing indications from 2013 estimates, -4.5% in the pre-market

(Finanza.com) Red of 4.5% in the Wall Street pre-market for Israel's Teva Pharmaceutical. The ADR (American depositary receipt) of the world's leading generic drug company is penalized by the release of estimates for 2013: according to the company, adjusted profit should amount to 4.85-5.15 dollars while turnover is estimated at 19.5-20.5 billion. The consensus of analysts on Wall Street is for a eps¹ of 5.65 dollars and a turnover of 20.8 billion.

Published November 30, 2012 –

Articoli correlati

Back to top button
Fedaiisf Federazione delle Associazioni Italiane degli Informatori Scientifici del Farmaco e del Parafarmaco